The Korean Liver Cancer Association and the National Cancer Center published revised treatment guidelines for hepatocellular carcinoma, at the Liver Week 2018 held at the Grand Hyatt Incheon on Friday.
The guidelines include new secondary therapies while presenting recommendations for monitoring examinations and supplementary therapies.
This revised guideline brought together 44 interdisciplinary experts to create 66 recommendations for 15 categories. Each recommendation was classified into three levels of evidence --A, B and C -- and a strong or weak recommendations standard based on clinical evidence.
Experts reviewed the medical evidence to date and put together evidence-centered opinions to make the guidelines, which will be used practically in treatment, research, and education of hepatocellular carcinoma.
The guidelines include recommendation grades and evidence-based evaluations regarding the efficacy and indications of Lenvatinib as a first-line treatment along with evaluations and recommendation grades of other second-line treatments such as Regorafenib, Nivolumab, Cabozantinib, and Ramucirumab.
The guidelines also evaluated adjuvant therapy with cytokine-induced killer cells, a new type of therapy. Recent findings on Sorafenib and concurrent treatment with conventional carotid chemotherapy are also included.
The guidelines mark the third revision of the ones, which were made in 2003 and revised in 2009 and 3014 by the two institutions.
<© Korea Biomedical Review, All rights reserved.>